Tectonic Therapeutic Inc (TECX)
NASDAQ:TECX
TECX Stock Chart & Stats
$29.44
-$0.66(-1.42%)
At close: 4:00 PM EST
$29.44
-$0.66(-1.42%)
Day’s Range― - ―
52-Week Range$13.70 - $36.03
Previous CloseN/A
Volume30.18K
Average Volume (3M)497.48K
Market Cap
$552.78M
Enterprise Value$312.09M
Total Cash (Recent Filing)$253.80M
Total Debt (Recent Filing)$1.28M
Price to Earnings (P/E)―
Beta1.33
Next Earnings
May 07, 2026EPS Estimate
-1.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding18,776,627
10 Day Avg. Volume324,145
30 Day Avg. Volume497,481
Financial Highlights & Ratios
PEG Ratio-1.69
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-6.34
Enterprise Value/Market Cap0.56
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.37
Forecast
1Y Price Target
$86.50Price Target Upside193.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-4.83
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial Design And EnrollmentAnalyst points out that the Phase 2 APEX trial targets patients with combined pre/post-capillary pulmonary hypertension and uses pulmonary vascular resistance as the primary endpoint, increasing the likelihood of detecting a meaningful treatment effect.
Pipeline DiversificationAnalyst notes that a Phase 1a healthy volunteer study for TX2100 is underway and that TX2100 is designed as a long-acting, subcutaneous APJ antagonist, which broadens the company's pipeline beyond the relaxin program.
Safety ProfileAnalyst highlights that a nonhuman primate toxicology study found no safety signals at the highest tested dose and independent safety reviews reported no concerns, supporting continued development of the lead program.
Bears Say
Cash Runway And Financing RiskAnalyst warns that high cash burn and a limited cash runway create financing risk that could pressure the stock and lead to dilutive capital raises.
Market Volatility From Short InterestAnalyst cautions that elevated short interest combined with a modest cash position could increase share-price volatility and amplify market pressure during financing events.
Mechanism Skepticism After Competitor FailureAnalyst notes that failure of a similar relaxin Fc-fusion in Phase 2 for lack of efficacy raises investor skepticism about the relaxin mechanism and could weigh on valuation for related programs.
Tectonic Therapeutic News
TECX FAQ
What was Tectonic Therapeutic Inc’s price range in the past 12 months?
Tectonic Therapeutic Inc lowest stock price was $13.70 and its highest was $36.03 in the past 12 months.
What is Tectonic Therapeutic Inc’s market cap?
Tectonic Therapeutic Inc’s market cap is $552.78M.
When is Tectonic Therapeutic Inc’s upcoming earnings report date?
Tectonic Therapeutic Inc’s upcoming earnings report date is May 07, 2026 which is in 43 days.
How were Tectonic Therapeutic Inc’s earnings last quarter?
Tectonic Therapeutic Inc released its earnings results on Feb 26, 2026. The company reported -$1.03 earnings per share for the quarter, beating the consensus estimate of -$1.088 by $0.058.
Is Tectonic Therapeutic Inc overvalued?
According to Wall Street analysts Tectonic Therapeutic Inc’s price is currently Undervalued.
Does Tectonic Therapeutic Inc pay dividends?
Tectonic Therapeutic Inc does not currently pay dividends.
What is Tectonic Therapeutic Inc’s EPS estimate?
Tectonic Therapeutic Inc’s EPS estimate is -1.16.
How many shares outstanding does Tectonic Therapeutic Inc have?
Tectonic Therapeutic Inc has 18,776,627 shares outstanding.
What happened to Tectonic Therapeutic Inc’s price movement after its last earnings report?
Tectonic Therapeutic Inc reported an EPS of -$1.03 in its last earnings report, beating expectations of -$1.088. Following the earnings report the stock price went down -2.006%.
Which hedge fund is a major shareholder of Tectonic Therapeutic Inc?
Currently, no hedge funds are holding shares in TECX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tectonic Therapeutic Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$86.50 (193.82% Upside)
$86.50 (193.82% Upside)
Blogger Sentiment
Bullish
TECX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 163.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $182.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.19%
12-Months-Change
Fundamentals
Return on Equity
-26.87%
Trailing 12-Months
Asset Growth
70.72%
Trailing 12-Months
Company Description
Tectonic Therapeutic Inc
Tectonic Therapeutic, Inc., a clinical stage biotechnology company focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G-protein coupled receptors(GPCRs). It offers GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's pipeline products include RXFP1 agonist, which is in ongoing phase 1a and 1b for the indication of heart failure with preserved ejection fraction; GPCR antagonist for indication of hereditary hemorrhagic telangiectasia; bi-functional GPCR modulator for indication of fibrosis; and GPCR modulators. Tectonic Therapeutic, Inc. is based in Watertown, Massachusetts.
TECX Stock 12 Month Forecast
Average Price Target
$86.50
▲(193.82% Upside)
Technical Analysis
Omeros
―
Abeona Therapeutics
―
Mereo Biopharma Group Plc
―
Foghorn Therapeutics
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
39.32% Insiders
13.72% Mutual Funds
30.28% Other Institutional Investors
10.81% Public Companies and Individual Investors
Options Prices
Currently, No data available
---